Skip to main content
Premium Trial:

Request an Annual Quote

Celera s Revenues Down, Losses Narrowed in Q4; Will Sell Rockville Facility

NEW YORK, July 28 (GenomeWeb News) - Celera Genomics today reported narrowed losses and a drop in revenues in the fourth quarter of its fiscal year 2004.

 

It also said that it was planning to sell its facility in Rockville, Md.

 

Celera, a unit of Applera, reported a net loss of $5.8 million for Q4 2004 as compared to $19.4 million in Q4 2003. The company said the Q4 results included a $24.8 million pre-tax gain associated with the  sale of its investment in Discovery Partners International, as well as an $18.1 million non-cash pre-tax charge representing the estimated loss on the planned Rockvillesale.

 

The $18.1 million write-off is due to losses Celera expects to incur after selling the two-building facility in Rockville. Robert Bennett, a spokesman for the company, said Celera bought the property at the height of the market and would sell it at a loss.

 

He also said the company would lease the facility from its new owners, and retain the proteomics and bioinformatics divisions that work there.

 

Celera's revenues decreased to $12.4 million in Q4 2004, from $21.5 million in the same quarter last year. The company attributed the losses primarily to continuing expiration of online and information business customer agreements.

 

The company saw a slight rise in its R&D spending in Q4 2004, to $29.4 million, from $28.5 million in Q4 2003. Celera said the rise was primarily to support preclinical development activities and the hiring of additional therapeutic R&D personnel.

 

As of June 30, Celera's cash and short-term investments totaled approximately $746 million.

 

Julia Karowcontributed to this report.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.